Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Read the full articleYou might also wanna read
Cathie Wood's Ark Invest buys $52 million position in surging tech stock as ARKK trails S&P 500 in 2024
Cathie Wood, chief of Ark Investment Management, is no stranger to buying into momentum.
miramarflnews.com·25d ago
Cathie Wood buys $38.1 million in Tesla shares during 7% stock decline
Cathie Wood, chief of Ark Investment Management, is known for buying "disruptive" tech stocks during market pullbacks.
miramarflnews.com·11d agoCathie Wood buys $38.1 million in Tesla shares during 7% stock decline
Cathie Wood, chief of Ark Investment Management, is known for buying "disruptive" tech stocks during market pullbacks.
miramarflnews.com·8d ago
ARK Invest Reshapes Portfolio with Focus on AI, Space, and Innovation Stocks
Cathie Wood ARK Invest sales spark investor interest as ARK reshapes holdings and doubles down on AI, space, and innovation stocks.
legalunitedstates.com·25d ago
Cathie Wood's ARK Invest holds $497M in Roku despite stock being 73% below all-time high
Cathie Wood has never been shy about making big bets on names that most of Wall Street hasn't fully figured out yet.
bit.ly·1mo ago
Cathie Wood defies SpaceX stock slump with a fresh $51M bet
Cathie Wood’s Ark Invest has purchased about $52.1 million of SpaceX stock, lifting its investment since the June IPO above $475 million as
Comments
Sign in to join the conversation.
No comments yet. Be the first.